NanoViricides (NYSE:NNVC) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of NanoViricides (NYSE:NNVC – Get Rating) in a research report issued on Sunday. The brokerage set a “sell” rating on the stock.

NanoViricides Price Performance

NNVC stock opened at $1.34 on Friday. NanoViricides has a 1 year low of $1.04 and a 1 year high of $3.88. The firm has a 50-day moving average of $1.34 and a 200 day moving average of $1.48. The company has a market cap of $15.60 million, a P/E ratio of -2.23 and a beta of 1.08.

Get NanoViricides alerts:

NanoViricides Company Profile

(Get Rating)

NanoViricides, Inc is a development stage company, which engages in the development of nanomedicine drugs against viruses. It focuses on anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs. The company was founded by Anil R.

Recommended Stories

• Get a free copy of the StockNews.com research report on NanoViricides (NNVC)
• MarketBeat Week in Review – 4/3 – 4/7
• Costco Sales Disappoint, Markets Are Missing This Upside Driver
• First Republic Bank Is A Speculative Play, Here’s Why
• The WD-40 Company Bottoms With Reversal In Sight 
• 3 Low-Cost Stock ETFs That Are Crushing It This Year

Receive News & Ratings for NanoViricides Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoViricides and related companies with MarketBeat.com's FREE daily email newsletter.